(Total Views: 762)
Posted On: 07/08/2017 5:26:48 PM
Post# of 102
Notes being converted and sold. That is why the downward fall the last 120 days. The CEO admitted it was a bad mistake.
Yes the company is worth more than the current market cap of 344k. The CEO mentioned in an interview they have 2 million dollars of inventory and that alone is worth more than the company at this point. Also more highlights below:
1) They have products on the shelves with Pet-Pain-Away and Nyloxin.
2) They are expanding in India and Canada this year.
3) They have an orphan drug which eliminated a lot of the cost to get FDA approval. They plan on phase II trials in the next few months. They have scientifically cloned the Cobra venom. This was the big thing that took so long to start trials. The FDA requires that you can make enough product that is needed before they will give a approval. Since the company was using real venom from snakes it was tough to keep up. They have now cloned it which is big.
4) They are working on new products for nerve agents and foot pain from heels.
6) They have patents in various countries.
There are not very many companies trading at .0009 that have all of the above. It's VERY undervalued and once dilution is done we are going to see a very fast explosion up. At this point we have to be close...
Yes the company is worth more than the current market cap of 344k. The CEO mentioned in an interview they have 2 million dollars of inventory and that alone is worth more than the company at this point. Also more highlights below:
1) They have products on the shelves with Pet-Pain-Away and Nyloxin.
2) They are expanding in India and Canada this year.
3) They have an orphan drug which eliminated a lot of the cost to get FDA approval. They plan on phase II trials in the next few months. They have scientifically cloned the Cobra venom. This was the big thing that took so long to start trials. The FDA requires that you can make enough product that is needed before they will give a approval. Since the company was using real venom from snakes it was tough to keep up. They have now cloned it which is big.
4) They are working on new products for nerve agents and foot pain from heels.
6) They have patents in various countries.
There are not very many companies trading at .0009 that have all of the above. It's VERY undervalued and once dilution is done we are going to see a very fast explosion up. At this point we have to be close...
(1)
(0)
